EGEGazette
Live
Report: Hurricane Polo hits Mexico: strong winds and flooding in Baja California SurReport: Russians strike school in Sumy with children sheltering inside — mediaReport: Hurricane Polo makes landfall on Mexico's Pacific coast, heads toward SonoraReport: Red alert in Catalonia: torrential rain floods the Penedès and cuts off metro and roads in BarcelonaIn brief: Myanmar: military air strike on market kills at least 50, humanitarian sources sayReport: Vessel struck by suspected projectile in Strait of HormuzReport: Fire breaks out on vessel hit by projectile in Strait of Hormuz: UK maritime agencyEthiopian Army Announces Control of Alamata Town in Tigray RegionStrong Explosions in Kyiv After Russian Ballistic Missile StrikesIn brief: Ethiopia: fighting intensifies between the TPLF and the federal army in TigrayMyanmar rebels report 49 killed in government troop strikesReport: Ethiopian army clashes with rebel alliance across multiple fronts
HealthReported

AI biotech Enveda raises $311M to advance nature-derived drugs into clinical trials

The funding round values the company at $2 billion as it pushes forward treatments for skin conditions and weight-loss maintenance after stopping GLP-1 drugs.

· 1 min read · language: en

Enveda, an AI-driven biotech company, has secured $311 million in new funding to advance its pipeline of nature-derived drugs into clinical trials, according to TechCrunch.

The funding round values the company at $2 billion, reflecting continued investor interest in AI-assisted approaches to drug discovery that draw on naturally occurring compounds rather than purely synthetic chemistry.

Among the treatments currently in testing are therapies for skin conditions, as well as drugs aimed at helping patients preserve weight loss after discontinuing GLP-1 medications, a class of drugs that has reshaped the weight-management treatment landscape in recent years.

The new capital is expected to support Enveda's efforts to move these candidate treatments further along the clinical trial process, a critical and often costly stage in bringing new drugs to market.

The raise adds to a broader wave of investment in AI-focused biotech companies, as the sector continues to attract significant funding on the premise that machine learning can accelerate the identification and development of viable drug candidates.

Sources

EGazette summarizes reporting from multiple sources; follow the links for the originals.

Comments

Sign in to join the conversation.

Forgot password?

No account?

Loading comments…

Related articles